INDIANA UNIVERSITY HEALTH
- Type
- Teaching hospital
- Where
- Indianapolis, IN
- Medicare CCN
- 150056
- Received
- $7,202,467 in 142 records, 2024 ($6,022,731 general, $1,179,735 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Indiana University Health, Inc. Fuzzy (name and state)
- Business registration: INDIANA UNIVERSITY HEALTH, INC Fuzzy (name and state)
- Business registration: INDIANA UNIVERSITY HEALTH, INC. Fuzzy (name and state)
- Business registration: INDIANA UNIVERSITY HEALTH, INC. Fuzzy (name and state)
- Business registration: INDIANA UNIVERSITY HEALTH, INC. Fuzzy (name and state)
- Business registration: INDIANA UNIVERSITY HEALTH, INC. Fuzzy (name and state)
- Business registration: INDIANA UNIVERSITY HEALTH, INC. Fuzzy (name and state)
- Nonprofit contractor: INDIANA UNIVERSITY HEALTH Fuzzy (name and state)
- Federal award recipient: INDIANA UNIVERSITY HEALTH INC Fuzzy (name and state)
- Federal award recipient: INDIANA UNIVERSITY HEALTH, INC. Fuzzy (name and state)
- Lobbying client: INDIANA UNIVERSITY HEALTH INC Fuzzy (name and state)
- Lobbying client: INDIANA UNIVERSITY HEALTH INC Fuzzy (name and state)
- Lobbying client: INDIANA UNIVERSITY HEALTH, INC. Fuzzy (name and state)
- Lobbying client: INDIANA UNIVERSITY HEALTH, INC. Fuzzy (name and state)
- Lobbying registrant: INDIANA UNIVERSITY HEALTH, INC. Fuzzy (name and state)
- Nonprofit: INDIANA UNIVERSITY HEALTH INC Fuzzy (name and state)
- Patent assignee: Indiana University Health, Inc. Fuzzy (name and state)
- Trademark owner: INDIANA UNIVERSITY HEALTH, INC. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 47 | $6,022,731 |
| 2024 | Research payment | 95 | $1,179,735 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Acquisitions | 1 | $3,506,742 |
| Grant | 5 | $2,269,659 |
| Research payment | 95 | $1,179,735 |
| Long term medical supply or device loan | 8 | $138,195 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 4 | $39,420 |
| Consulting Fee | 5 | $26,399 |
| Debt forgiveness | 7 | $21,299 |
| Space rental or facility fees (teaching hospital only) | 17 | $21,015 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $123,021 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2024 |
| 2024-12-31 | AngioDynamics, Inc. | $60,000 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2024 | |
| 2024-12-31 | AngioDynamics, Inc. | $60,000 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $27,884 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2024 |
| 2024-12-31 | Medline Industries LP | $18,287 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $5,040 | Long term medical supply or device loan | In-kind items and services | CORE Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $4,840 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7 | 2024 |
| 2024-12-31 | Stryker Corporation | $4,500 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $3,024 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2024 |
| 2024-12-31 | AngioDynamics, Inc. | $1,000 | Long term medical supply or device loan | In-kind items and services | Navigator Bionavigation System Device, Vascular Access | 2024 | |
| 2024-12-31 | Medline Industries LP | $733 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $577 | Long term medical supply or device loan | In-kind items and services | ISOTOUR Device, PATIENT CARE - PC | 2024 | |
| 2024-12-31 | Stryker Corporation | $577 | Long term medical supply or device loan | In-kind items and services | ISOTOUR Device, PATIENT CARE - PC | 2024 | |
| 2024-12-31 | Medline Industries LP | $550 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | COLOPLAST CORP | $337 | Debt forgiveness | Cash or cash equivalent | Titan Device, Men's Health | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $318 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7 | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $29 | Research payment | In-kind items and services | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab-Deruxtecan Dato- | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $13 | Research payment | In-kind items and services | ENHERTU Biological, Oncology | A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-DXd, DS-8201a | 2024 |
| 2024-12-27 | Janssen Research & Development, LLC | $5,600 | Research payment | Cash or cash equivalent | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial | 2024 | |
| 2024-12-24 | United Therapeutics Corporation | $2,015 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-12-11 | United Therapeutics Corporation | $2,145 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-12-04 | PFIZER INC. | $1,589 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2024 | |
| 2024-12-02 | Eli Lilly and Company | $31,500 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-02 | Perspectum Diagnostics Ltd | $3,407 | Research payment | Cash or cash equivalent | LiverMultiScan Device, Radiology | 2024 | |
| 2024-12-01 | Theratechnologies Inc. | $5,917 | Research payment | Cash or cash equivalent | TROGARZO Drug, HIV | A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab | 2024 |
| 2024-11-27 | Medtronic, Inc. | $4,773 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-11-27 | Medtronic, Inc. | $52 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-11-26 | United Therapeutics Corporation | $1,100 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-11-26 | QIAGEN, LLC | $38 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-11-25 | Gilead Sciences, Inc. | $12,938 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-11-25 | Perspectum Diagnostics Ltd | $135 | Research payment | In-kind items and services | LiverMultiScan Device, Radiology | Non-invasive quantification of liver health in NASH (N-QUAN): A prospective diagnostic accuracy study | 2024 |
| 2024-11-20 | Sumitomo Pharma America, Inc. | $6,050 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CAR | 2024 |
| 2024-11-20 | COLOPLAST CORP | $4,643 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-11 | Medtronic, Inc. | $9,023 | Research payment | Cash or cash equivalent | ACTIVA PC Device, Deep Brain Neurostimulation | PSR-DBS | 2024 |
| 2024-11-08 | Merck Sharp & Dohme LLC | $15,700 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7 | 2024 |
| 2024-11-05 | Eli Lilly and Company | $28,300 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2024 | |
| 2024-10-31 | Merck Sharp & Dohme LLC | $25,784 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2024 |
| 2024-10-31 | Barco, Inc. | $6,499 | Long term medical supply or device loan | In-kind items and services | 2024 | ||
| 2024-10-30 | United Therapeutics Corporation | $21,516 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-10-30 | United Therapeutics Corporation | $780 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-10-25 | National Marrow Donor Program | $7,915 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-10-24 | PFIZER INC. | $1,510 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2024 | |
| 2024-10-09 | Chiesi USA, Inc. | $14,000 | Research payment | Cash or cash equivalent | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 | |
| 2024-10-09 | Chiesi USA, Inc. | $2,500 | Research payment | Cash or cash equivalent | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 | |
| 2024-10-09 | United Therapeutics Corporation | $2,145 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-10-09 | Chiesi USA, Inc. | $750 | Research payment | Cash or cash equivalent | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 | |
| 2024-10-08 | Eli Lilly and Company | $32,449 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 | |
| 2024-09-30 | Merck Sharp & Dohme LLC | $15,803 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2024 |
| 2024-09-30 | Medtronic, Inc. | $1,250 | Research payment | Cash or cash equivalent | ACTIVA PC Device, Deep Brain Neurostimulation | PSR-DBS | 2024 |
| 2024-09-30 | Medtronic, Inc. | $1,250 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-09-27 | Cook Medical LLC | $437,033 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-09-25 | OPHTEC USA, Inc. | $1,755 | Research payment | Cash or cash equivalent | Artisan Aphakia Lens Device, Ophthalmology | Artisan Aphakia Lens for the Correction of Aphakia in Children | 2024 |
| 2024-09-25 | PFIZER INC. | $1,249 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2024 | |
| 2024-09-24 | Gilead Sciences, Inc. | $71,580 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-09-24 | Boston Scientific Corporation | $3,940 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_ENDO | MANTIS | 2024 |
| 2024-09-19 | Stryker Corporation | $3,506,742 | Acquisitions | Cash or cash equivalent | 2024 | ||
| 2024-09-06 | MOLNLYCKE HEALTH CARE US, LLC | $1,020 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Mepilex Border Sacrum Device, Wound Care | 2024 | |
| 2024-08-29 | Medtronic, Inc. | $3,162 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-08-29 | Medtronic, Inc. | $44 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-08-28 | COLOPLAST CORP | $4,533 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-08-28 | United Therapeutics Corporation | $2,145 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-08-27 | Eli Lilly and Company | $15,338 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION | 2024 | |
| 2024-08-27 | Boston Scientific Corporation | $1,292 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_ENDO | MANTIS | 2024 |
| 2024-08-26 | Medtronic, Inc. | $15,094 | Research payment | Cash or cash equivalent | ACTIVA PC Device, Deep Brain Neurostimulation | PSR-DBS | 2024 |
| 2024-08-22 | PFIZER INC. | $15,910 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | AN INTERNATIONAL MULTICENTER PROSPECTIVE NONINTERVENTIONAL STUDY OF REALWORLD TREATMENT OUTCOMES IN PATIENTS WITH METAST | 2024 |
| 2024-08-16 | Stryker Corporation | $2,637 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ALPHAVENT Device, SPORTS MEDICINE | 2024 | |
| 2024-08-16 | Stryker Corporation | $795 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NANOTACK FLEX Device, SPORTS MEDICINE | 2024 | |
| 2024-08-15 | Stryker Corporation | $6,117 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-08-12 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-08-09 | AstraZeneca Pharmaceuticals LP | $2,700 | Research payment | Cash or cash equivalent | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab-Deruxtecan Dato- | 2024 | |
| 2024-08-01 | Ascendis Pharma Endocrinology Inc | $5,841 | Research payment | Cash or cash equivalent | Skytrofa Drug, Endocrinology | foresiGHt extension | 2024 |
| 2024-08-01 | Theratechnologies Inc. | $1,000 | Research payment | Cash or cash equivalent | TROGARZO Drug, HIV | A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab | 2024 |
| 2024-07-31 | United Therapeutics Corporation | $1,365 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-07-31 | QIAGEN, LLC | $368 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-07-27 | PFIZER INC. | $2,999 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2024 | |
| 2024-07-26 | National Marrow Donor Program | $11,195 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-23 | Perspectum Diagnostics Ltd | $25,266 | Research payment | Cash or cash equivalent | LiverMultiScan Device, Radiology | 2024 | |
| 2024-07-23 | Boston Scientific Corporation | $1,310 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | OPTION | 2024 |
| 2024-07-22 | Cook Medical LLC | $1,648,108 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-07-12 | E.R. Squibb & Sons, L.L.C. | $4,594 | Research payment | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | Deliver Insights on Safety in Hypertrophic Cardiomyopathy and Observe Endpoints in Real World (DISCOVER-HCM) | 2024 |
| 2024-07-02 | Bolton Medical Inc | $5,712 | Research payment | Cash or cash equivalent | TREO ABDOMINAL STENT-GRAFT SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | PANTHER | 2024 |
| 2024-06-26 | PFIZER INC. | $2,531 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2024 | |
| 2024-06-26 | United Therapeutics Corporation | $2,210 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-06-25 | Boston Scientific Corporation | $3,019 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | OPTION | 2024 |
| 2024-06-25 | Boston Scientific Corporation | $3,000 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_ENDO | MANTIS | 2024 |
| 2024-06-12 | United Therapeutics Corporation | $9,100 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-06-12 | United Therapeutics Corporation | $4,085 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-06-06 | Ascendis Pharma Endocrinology Inc | $15,714 | Research payment | Cash or cash equivalent | Skytrofa Drug, Endocrinology | foresiGHt extension | 2024 |
| 2024-05-30 | Medtronic, Inc. | $3,774 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-05-30 | LivaNova USA, Inc. | $983 | Debt forgiveness | Cash or cash equivalent | Perfusion Tubing Device, Cardiology/Vascular Diseases | 2024 | |
| 2024-05-29 | COLOPLAST CORP | $4,841 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-05-29 | PFIZER INC. | $1,749 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2024 | |
| 2024-05-28 | Medtronic, Inc. | $2,500 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-05-28 | Boston Scientific Corporation | $1,266 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | OPTION | 2024 |
| 2024-05-27 | Janssen Research & Development, LLC | $4,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specificatio | 2024 |
| 2024-05-16 | Medtronic, Inc. | $12,435 | Research payment | Cash or cash equivalent | ACTIVA PC Device, Deep Brain Neurostimulation | PSR-DBS | 2024 |
| 2024-05-13 | Medical Device Business Services, Inc. | $1,800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2024 | |
| 2024-05-13 | Medical Device Business Services, Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2024 | |
| 2024-05-13 | Medtronic, Inc. | $750 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-05-13 | Medtronic, Inc. | $750 | Research payment | Cash or cash equivalent | ACTIVA PC Device, Deep Brain Neurostimulation | PSR-DBS | 2024 |
| 2024-05-01 | Theratechnologies Inc. | $1,379 | Research payment | Cash or cash equivalent | TROGARZO Drug, HIV | A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab | 2024 |
| 2024-04-29 | ZOLL Medical Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Defibrillator Device, Resuscitation | 2024 | |
| 2024-04-26 | Lilly USA, LLC | $100,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-04-26 | National Marrow Donor Program | $9,180 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-04-26 | PFIZER INC. | $1,249 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2024 | |
| 2024-04-22 | Boston Scientific Corporation | $4,400 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | OPTION | 2024 |
| 2024-04-22 | Cook Research Incorporated | $3,200 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-04-22 | Boston Scientific Corporation | $77 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | OPTION | 2024 |
| 2024-04-10 | E.R. Squibb & Sons, L.L.C. | $6,468 | Research payment | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes | 2024 |
| 2024-04-04 | Bolton Medical Inc | $4,052 | Research payment | Cash or cash equivalent | TREO ABDOMINAL STENT-GRAFT SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | PANTHER | 2024 |
| 2024-03-28 | Stryker Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-03-27 | United Therapeutics Corporation | $27,121 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-03-27 | Sumitomo Pharma America, Inc. | $15,953 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CAR | 2024 |
| 2024-03-27 | Sumitomo Pharma America, Inc. | $15,953 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CAR | 2024 |
| 2024-03-27 | PFIZER INC. | $1,249 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2024 | |
| 2024-03-19 | Ethicon US, LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DERMABOND Device, Wound Closure | 2024 | |
| 2024-03-14 | Ascendis Pharma Endocrinology Inc | $3,850 | Research payment | Cash or cash equivalent | Skytrofa Drug, Endocrinology | foresiGHt | 2024 |
| 2024-03-13 | AstraZeneca Pharmaceuticals LP | $8,150 | Research payment | Cash or cash equivalent | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with | 2024 | |
| 2024-02-29 | Medtronic, Inc. | $3,750 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-02-28 | PFIZER INC. | $5,937 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2024 | |
| 2024-02-19 | Draeger Medical Systems, Inc | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Babyroo TN300 Infant Radiant Warmer Device, Neonatal Care & Warming Therapy | 2024 | |
| 2024-02-15 | Medtronic, Inc. | $8,983 | Research payment | Cash or cash equivalent | ACTIVA PC Device, Deep Brain Neurostimulation | PSR-DBS | 2024 |
| 2024-02-14 | E.R. Squibb & Sons, L.L.C. | $47,283 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obst | 2024 | |
| 2024-02-12 | Eli Lilly and Company | $346,500 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-02-12 | Boston Scientific Corporation | $9,850 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_ENDO | MANTIS | 2024 |
| 2024-02-07 | COLOPLAST CORP | $9,181 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-02-07 | Bolton Medical Inc | $5,320 | Research payment | Cash or cash equivalent | TREO ABDOMINAL STENT-GRAFT SYSTEM Device, ENDOVASCULAR AORTIC REPAIR | PANTHER | 2024 |
| 2024-01-27 | PFIZER INC. | $1,249 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2024 | |
| 2024-01-26 | AstraZeneca Pharmaceuticals LP | $1,800 | Research payment | Cash or cash equivalent | ENHERTU Biological, Oncology | A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan T-DXd, DS-8201a | 2024 |
| 2024-01-23 | E.R. Squibb & Sons, L.L.C. | $8,775 | Research payment | Cash or cash equivalent | SOTYKTU Drug, Immunology | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic | 2024 |
| 2024-01-16 | Perspectum Diagnostics Ltd | $55,380 | Research payment | Cash or cash equivalent | LiverMultiScan Device, Radiology | 2024 | |
| 2024-01-16 | Boston Scientific Corporation | $8,636 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_ENDO | MANTIS | 2024 |
| 2024-01-16 | Theratechnologies Inc. | $4,978 | Research payment | Cash or cash equivalent | TROGARZO Drug, HIV | A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab | 2024 |
| 2024-01-12 | National Marrow Donor Program | $11,130 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-01-12 | Scientia Vascular | $6,401 | Research payment | Cash or cash equivalent | Scientia Vascular Registry Study | 2024 | |
| 2024-01-06 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2024 | |
| 2024-01-05 | Stryker Corporation | $2,575 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SAGE AIR TAP LC Device, MEDICAL | 2024 | |
| 2024-01-05 | Stryker Corporation | $720 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SAGE AIR TAP LC Device, MEDICAL | 2024 | |
| 2024-01-05 | Stryker Corporation | $720 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PREVALON Device, MEDICAL | 2024 | |
| 2024-01-05 | Stryker Corporation | $211 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SAGE AIR TAP LC Device, MEDICAL | 2024 | |
| 2024-01-05 | Stryker Corporation | $59 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SAGE AIR TAP LC Device, MEDICAL | 2024 | |
| 2024-01-05 | Stryker Corporation | $59 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SAGE AIR TAP LC Device, MEDICAL | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Indianapolis city, IN, county Marion County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Indianapolis city, IN | County Marion County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 885,860 | 975,809 | 6,851,073 |
| Population, 2020 census P1 | 887,642 | 977,203 | 6,785,528 |
| Median age B01002 | 34.3 | 34.4 | 38.1 |
| Under 18 B01001 | 24.8% | 25.0% | 23.3% |
| 65 and over B01001 | 13.1% | 13.2% | 16.8% |
| Households B11001 | 362,961 | 400,432 | 2,716,009 |
| Foreign born B05002 | 12.7% | 12.6% | 6.3% |
| Median household income B19013 | $66,219 | $66,346 | $71,957 |
| Median family income B19113 | $82,766 | $83,024 | $90,767 |
| Per capita income B19301 | $37,680 | $37,704 | $38,351 |
| Poverty rate B17001 | 15.8% | 15.3% | 12.3% |
| Unemployment rate B23025 | 5.1% | 5.0% | 4.3% |
| Civilian labor force B23025 | 472,847 | 520,799 | 3,472,016 |
| Mean commute (minutes) B08013 | 24.6 | 24.5 | 24.1 |
| Bachelor's degree or higher B15003 | 34.9% | 34.8% | 29.5% |
| Housing units B25001 | 401,428 | 441,040 | 2,976,568 |
| Owner-occupied B25003 | 56.0% | 56.5% | 70.6% |
| Renters B25003 | 44.0% | 43.5% | 29.4% |
| Median home value B25077 | $224,800 | $224,000 | $218,200 |
| Median gross rent B25064 | $1,156 | $1,153 | $1,062 |
| White, not Hispanic B03002 | 48.9% | 49.5% | 75.4% |
| Black B03002 | 27.6% | 27.1% | 9.1% |
| Hispanic or Latino B03002 | 13.8% | 13.8% | 8.6% |
| Asian B03002 | 4.2% | 4.0% | 2.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Indianapolis city, IN.
Comments